Cargando…

Aspirin in diabetic patients at primary prevention: insights of the VITAL cohort

PURPOSE: Aspirin use among patients with diabetes in primary prevention is still a matter of debate. We aimed to evaluate the potential cardiovascular risk benefit of aspirin in primary prevention, using data from a contemporary cohort. METHODS: Retrospective analysis of the VITAL cohort with > 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caldeira, D., Alves, M., Ferreira, J. J., Pinto, F. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261209/ https://www.ncbi.nlm.nih.gov/pubmed/36652191 http://dx.doi.org/10.1007/s40618-022-02001-3

Ejemplares similares

Aspirin for primary prevention of cardiovascular disease in diabetes
por: Xing, Ying, et al.
Publicado: (2019)

Aspirin in primary prevention of cardiovascular disease in diabetes
por: Papazafiropoulou, Athanasia K., et al.
Publicado: (2021)

Aspirin overutilization for the primary prevention of cardiovascular disease
por: VanWormer, Jeffrey J, et al.
Publicado: (2014)

Aspirin in primary prevention: USPSTF recommendations
por: Aalbers, J
Publicado: (2010)

Aspirin for primary prevention in the elderly
por: Saad, Marwan, et al.
Publicado: (2019)

Use of aspirin for primary prevention in patients with diabetes during the COVID-19 pandemic
por: Kow, Chia Siang, et al.
Publicado: (2021)

Aspirin for primary prevention in patients with high cardiovascular risk: insights from CORE-Thailand registry
por: Wongcharoen, Wanwarang, et al.
Publicado: (2023)

Aspirin for primary prevention of cardiovascular disease
por: Nansseu, Jobert Richie N., et al.
Publicado: (2015)

Aspirin in primary prevention: who is the target?
por: Gatto, Laura, et al.
Publicado: (2019)

Aspirin for primary prevention: Is this the end of the road?
por: Singal, Aayush Kumar, et al.
Publicado: (2019)

Aspirin for Primary Prevention of Cardiovascular Disease
por: Kim, Ji Hye, et al.
Publicado: (2019)

Evaluation of low-dose aspirin for primary prevention of ischemic stroke among patients with diabetes: a retrospective cohort study
por: Kim, Ye-Jee, et al.
Publicado: (2015)

Use of Aspirin and Statin as primary prevention for cardiovascular diseases
por: Alkhail, Bahaa Aba, et al.
Publicado: (2016)

Primary prevention of myocardial infarction: aspirin is not as useful as it seems
por: Luan, Yi, et al.
Publicado: (2020)

Aspirin for the Primary Prevention of Cardiovascular Events: A systematic review and meta-analysis comparing patients with and without diabetes
por: Calvin, Andrew D., et al.
Publicado: (2009)

Aspirin for Primary and Secondary Prevention of Mortality, Cardiovascular Disease, and Kidney Failure in the Chronic Renal Insufficiency Cohort (CRIC) Study
por: Taliercio, Jonathan J., et al.
Publicado: (2022)

Aspirin for Primary Prevention: A Challenging Decision
por: Pignone, Michael
Publicado: (2014)

Aspirin for the primary prevention of cardiovascular disease in the elderly
por: O’Sullivan, Jack W
Publicado: (2019)

Use and Misuse of Aspirin in Primary Cardiovascular Prevention
por: Coccheri, Sergio
Publicado: (2017)

Use of Preventive Aspirin Among Older US Adults With and Without Diabetes
por: Liu, Elizabeth Y., et al.
Publicado: (2021)

Low‐Dose Aspirin for Primary Prevention of Cardiovascular Disease: Use Patterns and Impact Across Race and Ethnicity in the Southern Community Cohort Study
por: Fernandez‐Jimenez, Rodrigo, et al.
Publicado: (2019)

Aspirin Use for Primary Cardiovascular Prevention During the COVID-19 Pandemic
por: Siegel, Arthur J.
Publicado: (2021)

Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
por: De Berardis, Giorgia, et al.
Publicado: (2009)

Use of Aspirin for Primary and Secondary Cardiovascular Disease Prevention in the United States, 2011–2012
por: Mainous, Arch G., et al.
Publicado: (2014)

Aspirin for Prevention of Preeclampsia
por: Atallah, A., et al.
Publicado: (2017)

POTENTIAL IMPLICATIONS OF ASPREE ON ASPIRIN PRIMARY PREVENTION GUIDELINES
por: Murray, Anne M
Publicado: (2019)

Aspirin for Primary Prevention of Cardiovascular Diseases: “WALTZ” with the Evidence
por: Dimitriadis, Kyriakos, et al.
Publicado: (2022)

Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2007)

Aspirin and prostate cancer prevention
por: Vidal, Adriana C., et al.
Publicado: (2015)

Aspirin for primary stroke prevention in elderly patients with vascular risk factors
por: Uchiyama, Shinichiro
Publicado: (2017)

Appropriateness of aspirin prescribing for primary and secondary prevention of cardiovascular disease in type 2 diabetes in different care settings
por: Tan, Shi Ying, et al.
Publicado: (2021)

Effect of carnosine, aminoguanidine, and aspirin drops on the prevention of cataracts in diabetic rats
por: Yan, Hong, et al.
Publicado: (2008)

Accuracy of Electronic Health Record–Documented Aspirin for Primary Prevention in Adult Outpatients
por: Chipalkatti, Naina, et al.
Publicado: (2023)

Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
Publicado: (2010)

The Efficacy And Safety Of Aspirin As The Primary Prevention Of Cardiovascular Disease: An Updated Meta-Analysis
por: Xie, Wenchao, et al.
Publicado: (2019)

Aspirin for the Primary Prevention of Cardiovascular Disease: Time for a Platelet-Guided Approach
por: Cofer, Lucas B., et al.
Publicado: (2022)

Aspirin Is Associated With Reduced Cardiovascular and All-Cause Mortality in Type 2 Diabetes in a Primary Prevention Setting: The Fremantle Diabetes Study
por: Ong, Greg, et al.
Publicado: (2010)

Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events among patients with type 2 diabetes in China
por: Jiang, Minghuan, et al.
Publicado: (2019)

Differential Effect of Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Diabetes Management: A subanalysis of the JPAD trial
por: Okada, Sadanori, et al.
Publicado: (2011)

A Systematic Review of Aspirin in Primary Prevention: Is It Time for a New Approach?
por: Brotons, Carlos, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_pluuipdgjcucfouftbt59o515a